Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome

Corcept Therapeutics24 enrolled

Overview

Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.

A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cushing's Syndrome

Interventions

No interventionOTHER

No treatment (intervention) was administered.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with ACTH independent endogenous Cushing's Syndrome * Available adrenal imaging prior to being treated with Korlym® * Treated with Korlym® and followed for at least 3 months (follow-up data should be available) Exclusion Criteria: * Diagnosed with adrenocortical carcinoma * Participant in any clinical trial(s) during the observational period

Outcomes

Primary Outcomes

Drug Utilization Patterns as assessed by chart review

The retrospective review would analyze the drug utilization patterns of patients treated with Korlym

Time frame: up to 4 years

Secondary Outcomes

Clinical Outcomes as assessed by chart review

The retrospective review would analyze outcomes measures (vitals, clinical assessments, etc) in patients treated with Korlym

Time frame: up to 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.